Login
$ATXI
$0.54 -$0.03 (4.48%) Close

Company Executives

$ATXI Management Team

Dr. Jay Kranzler

Non-Executive Chairman of the Board

Age 67
Compensation $174.5K USD
Sex Male

Dr. Alexandra Maclean

Chief Executive Officer

Director

Age 58
Compensation $840.1K USD
Sex Female

Mr. David Jin

Interim Chief Financial Officer

Chief Operating Officer

Age 35
Compensation $155.4K USD
Sex Male

Ms. Jaclyn Jaffe

Investor Relations

Age -
Compensation -
Sex Female
Directors
6
serving now
Independent
3 of 3
stated in the proxy; 3 not stated
Average tenure
Not stated
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2024 pay Source
Faith Charles
Not stated Not stated Independent None stated None stated $114,530
Neil Herskowitz
Not stated Not stated Independent None stated None stated $124,530
Jay Kranzler, M.D., PhD
Not stated Not stated Not stated None stated None stated $174,530
Alexandra MacLean, M.D.
Not stated Not stated Not stated None stated None stated Not stated
Curtis Oltmans
Not stated Not stated Independent None stated None stated $114,530
Lindsay A. Rosenwald, M.D.
Not stated Not stated Not stated None stated None stated $64,530

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

8 disclosed in the proxy filed Dec 5, 2025
Fortress
$3.0 million

Founders Agreement assigning IV tramadol license rights to the Company; Company assumed $3.0 million of Fortress debt and agreed to annual equity, financing equity and cash fees.

With the Company Open in proxy
Fortress
Amount not stated

Amended and Restated Founders Agreement and Exchange Agreement exchanging Fortress's Class A common shares for Common Stock and Class A Preferred Stock.

With the Company Open in proxy
Fortress
$0.5 million

Management Services Agreement under which Fortress provides advisory and consulting services for an annual consulting fee.

With the Company Open in proxy
Fortress
Amount not stated
2024

Financing equity fee shares issued to Fortress under the Founders Agreement.

With the Company Open in proxy
Fortress
$0.5 million
2024

Subscription and Forgiveness Agreement converting half of the amount owed under the MSA into common stock and forgiving the rest.

With the Company Open in proxy
Fortress
Amount not stated

Company acquired Baergic Bio, Inc. shares from Fortress in exchange for no cash or securities.

With the Company Open in proxy
Fortress
Amount not stated

Founders Agreement and Management Services Agreement with Baergic assigned to Avenue from Fortress.

With Baergic Open in proxy
Dr. Lindsay A. Rosenwald
a director on the Board
$53.775
2023

Purchase of 10,227 shares of common stock in the September 2023 Private Placement.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support